{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:48:13Z","timestamp":1793936893460,"version":"4.8.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jhep.2021.09.035","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T02:50:17Z","timestamp":1634093417000},"page":"353-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":292,"title":["Prognosis of patients with hepatocellular carcinoma treated with immunotherapy \u2013 development and validation of the CRAFITY score"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-5133","authenticated-orcid":false,"given":"Bernhard","family":"Scheiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2807-3565","authenticated-orcid":false,"given":"Katharina","family":"Pomej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha M.","family":"Kirstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7887-3440","authenticated-orcid":false,"given":"Florian","family":"Hucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Finkelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Waidmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Himmelsbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelius","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorben W.","family":"Fr\u00fcndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-2379","authenticated-orcid":false,"given":"Harald","family":"Heinzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Shmanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-1477","authenticated-orcid":false,"given":"Pompilia","family":"Radu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Siebenh\u00fcner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim C.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-9039","authenticated-orcid":false,"given":"Nuh N.","family":"Rahbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"K\u00fctting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk-Thomas","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias P.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Teufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Dosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1716-9166","authenticated-orcid":false,"given":"Tobias","family":"Meischl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6425","authenticated-orcid":false,"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-272X","authenticated-orcid":false,"given":"Nicola","family":"Personeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-1716","authenticated-orcid":false,"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Wege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.09.035_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000042","article-title":"Cancer and liver cirrhosis: implications on prognosis and management","volume":"1","author":"Pinter","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2021.09.035_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.035_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/apt.14913","article-title":"Review article: systemic treatment\u00a0of\u00a0hepatocellular carcinoma","volume":"48","author":"Pinter","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.09.035_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.jhep.2021.09.035_bib6","doi-asserted-by":"crossref","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate\u00a0459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts)\u00a0with advanced hepatocellular carcinoma","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib7","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.09.035_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.09.035_bib9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.035_bib10","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.035_bib12","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/apt.15245","article-title":"Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort","volume":"49","author":"Scheiner","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.09.035_bib13","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.3390\/cancers12123830","article-title":"Clinical and genetic tumor characteristics of responding and non-responding patients to PD-1 inhibition in hepatocellular carcinoma","volume":"12","author":"Spahn","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2021.09.035_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2021.09.035_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2021.09.035_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.jhep.2021.09.035_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-2607(97)00043-6","article-title":"Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions","volume":"54","author":"Heinzl","year":"1997","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jhep.2021.09.035_bib18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/hep.26057","article-title":"Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma","volume":"57","author":"Sieghart","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.035_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216677","article-title":"C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation","volume":"14","author":"Meischl","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.035_bib20","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/liv.14223","article-title":"Biology and significance of alpha-fetoprotein in hepatocellular carcinoma","volume":"39","author":"Galle","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.09.035_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cgh.2011.07.026","article-title":"Level\u00a0of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma","volume":"9","author":"Tyson","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.035_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244370","article-title":"C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib","volume":"15","author":"Hayashi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.035_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198812","article-title":"Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma","volume":"13","author":"Takada","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.035_bib24","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jhep.2021.09.035_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.jhep.2021.09.035_bib26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2021.09.035_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jhep.2021.09.035_bib28","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.035_bib29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.035_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2021.09.035_bib31","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2014.07.002","article-title":"How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma","volume":"61","author":"Hucke","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.035_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.amjsurg.2014.02.015","article-title":"Usefulness of a new inflammation-based scoring system for prognostication of patients with\u00a0hepatocellular carcinoma after hepatectomy","volume":"209","author":"Mori","year":"2015","journal-title":"Am J Surg"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2021.09.035_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.475","article-title":"Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): subanalyses of CheckMate-040","volume":"36","author":"El-Khoueiry","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib34","article-title":"IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo)\u00a0+ bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2021.09.035_bib36","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib37","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2012.06.022","article-title":"A\u00a0novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI)","volume":"57","author":"Pinato","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.035_bib38","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/liv.14220","article-title":"The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma","volume":"39","author":"Sanghera","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.09.035_bib39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2021.09.035_bib40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ccr.2007.08.008","article-title":"Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis","volume":"12","author":"Yang","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2021.09.035_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.1140485","article-title":"Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production","volume":"317","author":"Naugler","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.09.035_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","article-title":"Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression","volume":"140","author":"Park","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2021.09.035_bib43","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.23199","article-title":"Ikappa B kinasebeta\/nuclear factor-kappaB activation controls the development of liver metastasis by way of interleukin-6 expression","volume":"50","author":"Maeda","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.035_bib44","article-title":"C\u00a0reactive protein impairs adaptive immunity in immune cells of patients with melanoma","volume":"8","author":"Yoshida","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jhep.2021.09.035_bib45","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3389\/fimmu.2019.02183","article-title":"C-reactive protein promotes the expansion of myeloid derived cells with suppressor functions","volume":"10","author":"Jimenez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2021.09.035_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.suronc.2018.01.002","article-title":"Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: a comprehensive analysis of systemic inflammatory markers","volume":"27","author":"Akamine","year":"2018","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12885-020-6582-4","article-title":"Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab","volume":"20","author":"Morita","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2021.09.035_bib48","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3390\/cancers12082319","article-title":"C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a Bi-center study","volume":"12","author":"Riedl","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2021.09.035_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000531","article-title":"Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors","volume":"4","author":"Iivanainen","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2021.09.035_bib50","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib51","first-page":"2429","article-title":"The inhibition of apoptosis by alpha-fetoprotein (AFP) and the role of AFP receptors in anti-cellular senescence","volume":"14","author":"Laderoute","year":"1994","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jhep.2021.09.035_bib52","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s13277-013-0904-y","article-title":"Alpha-fetoprotein: a renaissance","volume":"34","author":"Terentiev","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jhep.2021.09.035_bib53","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.4049\/jimmunol.1400725","article-title":"Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells","volume":"193","author":"Pardee","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhep.2021.09.035_bib54","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s12032-010-9600-6","article-title":"Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status","volume":"28","author":"Shan","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib55","article-title":"Silencing alpha-fetoprotein inhibits VEGF and MMP-2\/9 production in human hepatocellular carcinoma cell","volume":"9","author":"Meng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.035_bib56","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2021.09.035_bib57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Emerging Risk Factors","year":"2010","journal-title":"Lancet"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:42:59Z","timestamp":1759174979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821021000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0168827821021000"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.09.035","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy \u2013 development and validation of the CRAFITY score","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}